# Juvenile idiopathic arthritis (referral) - Category: chronic - Review status: reviewed (every claim checked against a document named on this page) - Sources: Juvenile Idiopathic Arthritis - StatPearls (NCBI Bookshelf NBK554605) - https://www.ncbi.nlm.nih.gov/books/NBK554605/ · Ibuprofen 100 mg/5 ml Oral Suspension SmPC section 4.2 (eMC product 4560) (juvenile rheumatoid arthritis dose) · Juvenile idiopathic arthritis - disease-level clinical article (juvenile-idiopathic-arthritis-referral-full.txt) · Juvenile idiopathic arthritis - disease-level clinical article (juvenile-idiopathic-arthritis-referral-clinical.txt) - Verified date: 2026-09 ## Verified against - Ibuprofen 100 mg/5 ml Oral Suspension SmPC section 4.2 (eMC product 4560) (juvenile rheumatoid arthritis dose) - Juvenile Idiopathic Arthritis - StatPearls (NCBI Bookshelf NBK554605) - https://www.ncbi.nlm.nih.gov/books/NBK554605/ - Juvenile idiopathic arthritis - disease-level clinical article (juvenile-idiopathic-arthritis-referral-full.txt) ## Treatment metadata - Ibuprofen — 100 mg — oral.liquid - Referral & safety-netting (no drug therapy) ## Complete treatment card ```text JUVENILE IDIOPATHIC ARTHRITIS (REFERRAL) Sources: Juvenile Idiopathic Arthritis - StatPearls (NCBI Bookshelf NBK554605) - https://www.ncbi.nlm.nih.gov/books/NBK554605/ · Ibuprofen 100 mg/5 ml Oral Suspension SmPC section 4.2 (eMC product 4560) (juvenile rheumatoid arthritis dose) · Juvenile idiopathic arthritis - disease-level clinical article (juvenile-idiopathic-arthritis-referral- full.txt) · Juvenile idiopathic arthritis - disease-level clinical article (juvenile- idiopathic-arthritis-referral-clinical.txt) Review status: REVIEWED against 3 sources listed above (2026-09) IS IT THIS? - reference only, to read alongside your own examination SYMPTOMS - what the patient reports (5) - Course is unpredictable - some children have self-limiting disease, others unremitting arthritis with a high risk of joint destruction - Diagnosis is considered in children under 16 with arthritis persisting at least six weeks, once other causes of chronic arthritis are excluded - Joint aches are common early in systemic JIA, though frank arthritis is not always obvious yet [joint pain] - In systemic JIA the wrists, knees, and ankles are most typically affected, though hands, hips, cervical spine, and the jaw joint can also be involved - unlike the oligo- and polyarticular subtypes - Joint pain and soft-tissue pain make up about 65% of musculoskeletal complaints in children seen in general practice [joint pain] SIGNS - what you find (8) - JIA shows the typical inflammatory-arthritis picture: synovial inflammation, joint fluid, soft-tissue puffiness, thinned bone, marrow edema, and areas of erosion [oedema] - Developmental features unique to JIA include epiphyseal growth disturbance, early physeal fusion, and limb-length discrepancy - Systemic arthritis presents with fever of at least 2 weeks plus at least one of: a fleeting pink rash, generalized lymph node enlargement, an enlarged liver or spleen, or serositis [fever · hepatomegaly · rash] - Psoriatic arthritis is diagnosed with chronic arthritis plus psoriasis, or with at least 2 of dactylitis, nail pitting, onycholysis, or a first-degree relative with psoriasis [nail changes] - Enthesitis-related arthritis needs arthritis with enthesitis, or either plus at least 2 of: SI joint or lumbosacral pain, positive HLA-B27, onset in a boy over 6, uveitis, or a related spondyloarthropathy history - Oligoarthritis affects four or fewer joints in the first six months of disease - RF-negative polyarthritis involves five or more joints in the first six months with a negative IgM rheumatoid factor - RF-positive polyarthritis is five or more joints in the first six months with a positive IgM rheumatoid factor on two tests three months apart TESTS (10) - There is no single test that confirms JIA or predicts how active the disease will be - Initial labs are CBC, ESR, CRP, ANA, rheumatoid factor, anti-CCP antibodies, and HLA-B27 - A positive RF or anti-CCP adds little to the diagnosis itself but can flag a worse disease course - Ferritin, fibrinogen, AST, and triglycerides are checked when macrophage activation syndrome is a concern - X-ray changes are often undetectable early on; indirect signs are soft-tissue swelling and displaced fat pads, with osteoporosis, joint-space narrowing, erosion, and subluxation appearing later - Ultrasound is radiation-free, allows comparing both sides, and can assess synovial thickening, effusion, tenosynovitis, enthesitis, and bone erosions - On ultrasound, synovitis and thickened synovium appear as abnormally dark tissue near joint lines or tendons - Ultrasound can also guide intra-articular steroid injections and does not require sedating the child - MRI is the only imaging modality that can show bone marrow edema and is also the most sensitive for detecting erosions - Standard MRI protocol needs T1 spin-echo, a fat-suppressed sequence, and pre- and post- contrast fat-suppressed T1 sequences IF NOT THIS - what else fits (5) - Oligoarthritis mimics to rule out include reactive arthritis, Lyme arthritis, rheumatic fever, toxic and septic arthritis, pyomyositis, steroid-induced bone death, sickle cell disease, hemophilia, scurvy, and osteomyelitis - Polyarthritis mimics to rule out include reactive arthritis, Lyme arthritis, rheumatic fever, scurvy, multifocal osteomyelitis, non-accidental injury, lupus, mixed connective tissue disease, Sjogren syndrome, scleroderma, and sarcoidosis - Systemic arthritis mimics to rule out include mycoplasma, cat-scratch disease, endocarditis, Lyme disease, rheumatic fever, PFAPA periodic fever, autoinflammatory syndromes, and vasculitis like polyarteritis nodosa or Kawasaki disease - Systemic arthritis can also mimic inflammatory bowel disease, malignancies such as leukemia, lymphoma, or neuroblastoma, or Castleman disease - Enthesitis-related arthritis mimics include apophysitis (Osgood-Schlatter, Sever disease), inflammatory bowel disease, chronic recurrent multifocal osteomyelitis, and amplified musculoskeletal pain syndrome Source Juvenile idiopathic arthritis - disease-level clinical article (juvenile-idiopathic- arthritis-referral-full.txt) Status traced to the source above Rx: Symptom relief while the referral is arranged | Referral and safety-netting SYMPTOM RELIEF WHILE THE REFERRAL IS ARRANGED 1. IBUPROFEN [1st line] Adult Not applicable - juvenile idiopathic arthritis is by definition a disease beginning under 16 years of age (see the paediatric dose) - Not applicable Peds 30-40 mg/kg/day (Divided into three or four doses across the day, as an anti- inflammatory rather than an analgesic amount - the same SmPC gives only 20 mg/kg/day in divided doses for ordinary pain and fever. The SmPC states no milligram ceiling for the juvenile arthritis dose, so none is applied here; see the cautions for what that means in a heavier child. Do not give ibuprofen to a child under 3 months.) 3kg -> 90-120 mg/day 4kg -> 120-160 mg/day 5kg -> 150-200 mg/day 6kg -> 180-240 mg/day 7kg -> 210-280 mg/day 8kg -> 240-320 mg/day 9kg -> 270-360 mg/day 10kg -> 300-400 mg/day 11kg -> 330-440 mg/day 12kg -> 360-480 mg/day 13kg -> 390-520 mg/day 14kg -> 420-560 mg/day 15kg -> 450-600 mg/day 16kg -> 480-640 mg/day 17kg -> 510-680 mg/day 18kg -> 540-720 mg/day 19kg -> 570-760 mg/day 20kg -> 600-800 mg/day 21kg -> 630-840 mg/day 22kg -> 660-880 mg/day 23kg -> 690-920 mg/day 24kg -> 720-960 mg/day 25kg -> 750-1000 mg/day 26kg -> 780-1040 mg/day 27kg -> 810-1080 mg/day 28kg -> 840-1120 mg/day 29kg -> 870-1160 mg/day 30kg -> 900-1200 mg/day 31kg -> 930-1240 mg/day 32kg -> 960-1280 mg/day 33kg -> 990-1320 mg/day 34kg -> 1020-1360 mg/day 35kg -> 1050-1400 mg/day 36kg -> 1080-1440 mg/day 37kg -> 1110-1480 mg/day 38kg -> 1140-1520 mg/day 39kg -> 1170-1560 mg/day 40kg -> 1200-1600 mg/day 41kg -> 1230-1640 mg/day 42kg -> 1260-1680 mg/day 43kg -> 1290-1720 mg/day 44kg -> 1320-1760 mg/day 45kg -> 1350-1800 mg/day 46kg -> 1380-1840 mg/day 47kg -> 1410-1880 mg/day 48kg -> 1440-1920 mg/day 49kg -> 1470-1960 mg/day 50kg -> 1500-2000 mg/day Choice Alternatives. The article names no individual NSAID, so any of the class would answer its recommendation; ibuprofen leads because it is the one with a licensed juvenile rheumatoid arthritis dose in a paediatric liquid, and it is stocked everywhere in Egypt. The drugs that actually change the disease - methotrexate and the biologics - are named by the article without any dose and are started by rheumatology, not here. Source Ibuprofen 100 mg/5 ml Oral Suspension SmPC section 4.2 (eMC product 4560) for the juvenile arthritis amount: "For Juvenile Rheumatoid Arthritis (prescription only use): Doses up to 30-40mg/kg/day may be taken in three or four divided doses." That an NSAID is the initial symptomatic treatment for every subtype comes from Juvenile Idiopathic Arthritis - StatPearls (NCBI Bookshelf NBK554605) - https://www.ncbi.nlm.nih.gov/books/NBK554605/ Why The article: "Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mainstay of initial symptomatic treatment for all subtypes." It names no individual NSAID and states no amount, so the amount comes from the product licensed for juvenile rheumatoid arthritis - the anti-inflammatory dose, which is roughly twice the ordinary dose for pain and fever. This is what primary care can give while the rheumatology referral is arranged; it treats the symptoms and changes nothing about the disease. Caution No milligram ceiling is stated for this indication, and the calculated figure gets large in an older child. The same SmPC caps ordinary analgesic use in an adult at "not more than 1200 mg (60 ml) in any 24 hour period", and separately warns that "use of Ibuprofen, particularly at a high dose (2400 mg/day) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke)". Those are an analgesic cap and a cardiovascular risk threshold, not a licensed maximum for juvenile arthritis - so where the weight-based figure above lands near or above them, agree the actual dose with the rheumatology team rather than using the calculated figure. This is symptom relief, not treatment of the disease. It does not remove the need for the referral and it does not slow joint damage. Usual NSAID precautions. Give it with food; avoid in active peptic ulceration, in a bleeding disorder, and in a dehydrated child; take care in asthma, and stop it if the child develops abdominal pain, black stools or a rash. RED FLAG - Do not let an NSAID mask a septic joint or a malignancy. A swollen joint plus fever, night pain, bruising or pallor is investigated before it is treated - the article's own differential for a few swollen joints includes septic arthritis, osteomyelitis, non-accidental injury, leukaemia, lymphoma and neuroblastoma. Egypt NOVA-PROFEN 100MG/5ML ORAL SUSP. 100ML SANOFI 2.25 EGP IBUPROFEN 100MG/5ML SUSP. 120 ML SEDICO 5.00 EGP MARCOFEN 100MG/5ML SUSP. 120ML GLAXO SMITHKLINE 5.85 EGP MAFO 100MG/5ML SYRUP 100 ML EIPICO 25.00 EGP IBUCALMIN 100MG/5ML SYRUP 120 ML MASH PREMIERE 28.00 EGP JUSPOLED 100MG/5ML SYRUP 120 ML EGPI > JASPER... 31.00 EGP MEGAFEN-N 100MG/5ML SUSP. 120 ML RAMEDA 35.00 EGP BRUFEN 100MG/5ML SYRUP 150ML KAHIRA > ABBO... 44.00 EGP BRUFEMOL-N SUSP. 60 ML ARAB DRUG COM... 4.50 EGP -> ? strength differs, ? different route - not oral liquid IBUFEN 2% SUSP. 60ML ALEXANDRIA 4.50 EGP -> ? strength differs, ? different route - not oral liquid REFERRAL AND SAFETY-NETTING 2. REFERRAL & SAFETY-NETTING (NO DRUG THERAPY) [2nd line] Adult Source No dose - the referral threshold and the mimics to exclude, from Juvenile Idiopathic Arthritis - StatPearls (NCBI Bookshelf NBK554605) - https://www.ncbi.nlm.nih.gov/books/NBK554605/ Why A joint that has been swollen for six weeks in a child under 16 is a rheumatology referral, and the six weeks is the whole definition. Primary care's job is to reach that threshold without treating the child as a series of sprains, and to exclude infection and malignancy on the way. Disease-modifying therapy is specialist-initiated. Caution THE DEFINITION IS THE REFERRAL THRESHOLD - juvenile idiopathic arthritis (JIA) is a mixed group of inflammatory arthritides of unknown cause, arising in a child under 16 and running 6 weeks or more. Consider it in any child under 16 years whose arthritis has lasted at least six weeks, once the other causes of a chronic arthritis have been excluded. IT IS A DIAGNOSIS OF EXCLUSION, SO THE DANGEROUS MIMICS COME FIRST - because JIA is arrived at by ruling everything else out, any positive answer in the systems review has to be chased down as a possible disease in its own right. For a few swollen joints, the article's own list runs to infection in the joint or the muscle, osteomyelitis, sickle cell disease and haemophilia, injury that was not accidental, and the malignancies - a bone tumour, neuroblastoma, leukaemia, lymphoma. A child with a swollen joint and night pain, bruising or pallor is investigated for leukaemia before being labelled arthritic. AND FOR A FEVERISH CHILD WITH JOINTS, THE LIST IS DIFFERENT AGAIN - before systemic arthritis is accepted, exclude infection (mycoplasma, cat scratch disease, endocarditis, Lyme disease); acute rheumatic fever; PFAPA, that is periodic fever with mouth ulcers, sore throat and neck nodes; the other autoinflammatory syndromes; systemic vasculitis, meaning polyarteritis nodosa and Kawasaki disease; inflammatory bowel disease; and malignancy - leukaemia, lymphoma, neuroblastoma. WHAT THE JOINTS LOOK LIKE - JIA follows the usual pattern of an inflammatory joint disease: synovitis, an effusion, swelling of the soft tissue, thin bone, oedema within the bone, erosions. To that, a growing skeleton adds its own: growth at the epiphysis disturbed, a physis that fuses too soon, and limbs that end up different lengths. The wrists, the knees and the ankles are where it most typically sits. NO BLOOD TEST MAKES OR EXCLUDES THE DIAGNOSIS - nothing on the panel is specific, either for making the diagnosis or for judging how active the disease is. A positive rheumatoid factor or anti-CCP adds little diagnostically, though it does point to a rougher course and a worse outcome. What to send: a full blood count, ESR, CRP, antinuclear antibody, rheumatoid factor, anti-CCP antibodies, and HLA-B27. A NORMAL X-RAY EARLY ON MEANS NOTHING - the plain film is still where imaging starts for a painful joint, but early in JIA there is nothing on it to find. Ultrasound is the accessible next step: it shows the thickened synovium and the synovitis, which matters greatly for the diagnosis, and it can be done without sedating the child. WHAT PRIMARY CARE CAN OFFER WHILE THE REFERRAL IS ARRANGED - whatever the subtype, symptomatic treatment starts with a non-steroidal anti-inflammatory. The article names no individual NSAID and states no amount; the ibuprofen entry above carries the amount from the product licensed for juvenile rheumatoid arthritis, which is an anti- inflammatory dose and not the smaller one used for pain and fever. AND THE REST OF THE TREATMENT IS NOT A CLINIC DECISION - treating JIA takes drugs that damp inflammation and modulate the immune system, physiotherapy alongside them, and in time possibly an operation, help with nutrition, and psychosocial support. Reliance on NSAIDs has fallen away as treatment has grown more aggressive - methotrexate and the biologics. KEEP THE CHILD MOVING - physiotherapy works the joints through their range while loading them as little as possible, and swimming often suits that well. Moderate exercise for fitness, for suppleness and for strength is part of it. MACROPHAGE ACTIVATION SYNDROME IS THE ONE THAT KILLS - the most frightening complication of the lot, driven by T lymphocytes and macrophages activating and multiplying out of control. Nobody knows how often it happens in JIA, though some studies put it as high as 10% of cases. The tests it calls for are ferritin, fibrinogen, AST and triglycerides. THE LONG-TERM DAMAGE IF IT DRIFTS - the two seen most are legs of unequal length and a contracted joint. Others that matter: growth held back, bone mineral density below what the child's age should give, hips damaged badly enough to need replacing, and amyloidosis. WHICH IS WHY THE REFERRAL IS URGENT RATHER THAN ROUTINE - diagnosing and treating this quickly, and correctly, is what keeps a joint from being damaged for good and keeps it working. EYE INVOLVEMENT - ASK THE RHEUMATOLOGIST TO ARRANGE THE EYE REVIEW. The cached article records genetic ground shared by JIA and uveitis, naming HLADRB1:11 and HLADRB1:13 as linked to uveitis, and it reports uveitis commonest in northern and southern Europe and least common in Latin America, in Africa, in the Middle East and in Southeast Asia. It sets out no screening interval and no examination method, so no schedule is printed here; the interval comes from the specialist who takes the child on. Prices are indicative (dataset snapshot 2026-06); verify with the pharmacy. ``` --- Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement. [Privacy policy](/privacy)